Ratings MedinCell S.A.

Equities

MEDCL

FR0004065605

Market Closed - Euronext Paris Other stock markets 11:35:20 2024-05-06 am EDT			5-day change	1st Jan Change
14.62 ^EUR	+2.24%		+5.94%	+103.06%

Apr. 17	Medincell: share price rises following agreement with AbbVie	CF
Apr. 16	Medincell, AbbVie to Co-Develop Injectable Therapeutics	DJ

Summary

Overall, the company has poor fundamentals for a medium to long-term investment strategy.

Strengths

The prospective high growth for the next fiscal years is among the main assets of the company
Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
For several months, analysts have been revising their EPS estimates roughly upwards.
Analysts covering this company mostly recommend stock overweighting or purchase.
Over the past four months, analysts' average price target has been revised upwards significantly.

Weaknesses

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
The company has insufficient levels of profitability.
The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
The company's "enterprise value to sales" ratio is among the highest in the world.
The average consensus view of analysts covering the stock has deteriorated over the past four months.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
MEDINCELL S.A.	+103.06%	443M	-
ELI LILLY AND COMPANY	+31.52%	662B	C+
NOVO NORDISK A/S	+21.96%	546B	B
JOHNSON & JOHNSON	-5.21%	359B	C+
MERCK & CO., INC.	+17.02%	323B	B-
ABBVIE INC.	+5.01%	289B	C+
ASTRAZENECA PLC	+13.68%	234B	B+
NOVARTIS AG	+3.81%	198B	B-
ROCHE HOLDING AG	-10.63%	194B	A+
AMGEN INC.	+3.98%	167B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes